Status and phase
Conditions
Treatments
About
To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
Full description
Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4 weeks.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following prior condition are excluded:
Abnormal chest x-ray consistent with active opportunistic infection within 6 weeks prior to study entry.
Prior Medication:
Excluded:
Required:
Required:
Significant active alcohol or drug abuse sufficient to prevent study compliance.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal